Aphria (TSX:APHA; NYSE:APHA) has launched CannRelief, a cannabidiol (CBD)-based nutraceutical and cosmetics line, through its subsidiary Aphria Deutschland. Featuring hemp-derived CBD, CannRelief products are produced...
The European Medicine Agency’s (EMA) advisory committee (CHMP) affirmed that a 1gm daily dose of omega-3s are not effective in preventing further cardiovascular (CV) problems in patients who have had a heart attack. The...
Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...
Closely-held Lutronic Vision retained professor Robyn Guymer, a world-renowned age-related macular degeneration (AMD) expert and key opinion leader, to serve as the principal investigator for its planned pilot clinical...
Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...
GeoVax Labs (OTCQB:GOVX) published research showing that a single intramuscular dose of its Ebola vaccine, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus. GEO-EM01...
Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo...
Moleculin Biotech (NASDAQ:MBRX) has treated the first patients in its European Phase 1/2 clinical trial of Annamycin for relapsed and refractory acute myeloid leukemia (AML). The company also submitted a request to the...
Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...